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Abstract
Objective To compare the effects of an angiotensin receptor
blocker(ARB)-based regimen versus a non-ARB based
regimen on diastolic function and neurohormones in
patients with hypertension and diastolic dysfunction.
Methods 97 patients with a systolic blood pressure (SBP)
≥140 mmHg, a left ventricular ejection fraction >0.50, and
echocardiographic evidence of diastolic dysfunction were
randomly assignment to open-label treatment with eprosar-
tan (with other anti-hypertensives; n=47) or other anti-
hypertensives alone (n=50). Echocardiography, including
tissue Doppler imaging (TDI), and neurohormones were
done at baseline and after 6 months.
Results Mean age was 65 (±10) years and 64% was
female. During 6 months of treatment, SBP decreased
from 157±16 to 145±18 mmHg in the eprosartan group
a n df r o m1 5 8 ± 1 7t o1 4 1 ± 1 8m m H gi nt h ec o n t r o lg r o u p
(both p<0.001; p = ns between groups). Diastolic function
was unaffected in both groups and there was no
correlation between changes in SBP and changes in mean
TDI (r=−0.06; p=0.58). Aldosterone levels decreased in
the eprosartan group, but other neurohormones remained
largely unchanged. Change in SBP was however related to
the change in NT-proBNP (r=0.26; p=0.019).
Conclusion Lowering blood pressure, either with eprosar-
tan or other anti-hypertensives in hypertensive patients with
diastolic dysfunction did not change diastolic function after
6 months of treatment, but was associated with a decrease
of NT-proBNP.
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Introduction
Long-term hypertension is often accompanied by an
impaired relaxation of the ventricles due to diastolic
dysfunction. The presence of diastolic dysfunction, in
particular when measured with tissue Doppler, is not only
related to a greater risk of the development of heart failure,
but is also associated with a poor prognosis [1].
Diastolic dysfunction is often present in combination
with hypertension and left ventricular hypertrophy. Several
antihypertensive agents have proven to effectively reduce
left ventricular hypertrophy. However, meta-analyses have
indicated that with the same blood pressure reduction,
angiotensin receptor blockers are more effective in the
reduction of left ventricular hypertrophy than other antihy-
pertensive drugs [2]. In addition, angiotensin receptor
blockers have more pronounced effects on the reduction
of myocardial fibrosis compared with other anti-
hypertensives [3–5]. Therefore, the effects of angiotensin
receptor blockers on diastolic function are expected to be
better than other anti-hypertensive drugs.
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DOI 10.1007/s10557-010-6221-4A few smaller studies demonstrated beneficial effects of
losartan, irbesartan, and telmisartan on diastolic function
[6–12]. However, a recent randomised clinical trial did not
demonstrate superiority of an angiotensin receptor blocker
over control therapy in improving diastolic function in
patients with hypertension and diastolic dysfunction [13].
Despite a slightly larger drop in blood pressure in the
valsartan group, there was no difference in diastolic function
after 9 months of treatment. Whether treatment in VALIDD
was related to changes in neurohormonal activation remains
unknown, since no data on neurohormonal changes were
reported. This can be important, since changes in (NT-pro)
BNP and other neurohormones might indicate an early
change in cardiac filling pressures, potentially leading to
structural and functional cardiac changes.
We conducted a prospective, randomised study to
evaluate the effects of the angiotensin receptor blocker
eprosartan versus control anti-hypertensive therapy on
diastolic function and neurohormonal changes in patients
with hypertension and diastolic dysfunction.
Methods
Design
The “effects of Eprosartan on Echocardiographic and Neuro-
hormonal parameters of Diastolic dysfunction in hypertensive
patients (EEND) study” was a prospective, randomised, open
label trial, with blinded endpoint evaluation (PROBE).
Patients
From 2004 to 2007, 97 patients with hypertension and signs
of diastolic dysfunction were randomised in three centres in
the Netherlands. Patients older than 18 years, with
hypertension (blood pressure ≥ 140/90), who were not yet
treated with an angiotensin II-AT1 receptor antagonist,
underwent routine echocardiography and were screened for
signs of diastolic dysfunction.
Patients were eligible to participate if left ventricular
ejection fraction (LVEF) was >50%, and E/A-ratio was <1
incombinationwitheitheradecelerationtime(DCT)>280ms
or an isovolumetric relaxation time (IVRT) >105 ms. Exclu-
sion criteria were recent myocardial infarction (<6 weeks),
unstable angina pectoris, severe valvular disease, acute heart
failure, atrial fibrillation, pacemaker, history of drug-
sensitivity or allergy for eprosartan, pregnancy of lactation,
clinical significant liver or renal disease, infection, and
previous poor quality echocardiogram. Patients were random-
ized between eprosartan 600 mg once daily (400 mg 2 weeks
loading dose) and other anti-hypertensives (n=47) or other
anti-hypertensives alone (n=50) for a period of 6 months.
Other anti-hypertensives that were allowed included ACE-
inhibitors, β-blockers, diuretics, calcium antagonists, but not
ARBs. This study protocol was approved by the institutional
review committee and all patients provided written informed
consent.
Procedures
Patients were screened at the outpatient of the St. Antonius
Hospital, Nieuwegein, the University Medical Centre
Groningen, Refaja Hospital Stadskanaal, the Netherlands.
All patients who met the screening criteria signed
informed consent and were referred for echocardiographic
screening. After echocardiography, a baseline visit was
performed, which included medical history, current medi-
cation use, physical examination, including systolic and
diastolic blood pressure measurements (mean of three
recordings after 5 min in supine position); ECG, routine
laboratory screening, including haemoglobin, haematocrit,
creatinin, urea, sodium, potassium, cholesterol, LDL-
cholesterol, and triglycerides.
Patients who fulfilled all inclusion and exclusion criteria
were randomized to eprosartan or control treatment. Eprosar-
tan was administered as 400 mg once daily during the first
2weeks,anduptitratedto600mgoncedaily,unlesstherewere
side effects. Additional anti-hypertensive therapy was allowed
when the control blood pressure of <140/90 mmHg was not
achieved.Inthecontrolarm,allotheranti-hypertensiveagents,
except angiotensin receptor blockers, were allowed to reach
the target blood pressure of <140/90 mmHg.
After 6 weeks, a second outpatient clinic visit was
performed, including changes in medication, registration of
(serious) adverse events, medical history, physical examina-
tion. ECG, and routine laboratory screening. At 6 months, a
final outpatient visit was performed, including the same
assessments as the 6 weeks visit, and in addition an
echocardiogram was performed. No patient was lost during
follow-up.
Echocardiography
Patients underwent two-dimensional echocardiography,
including colour flow mapping 2D-guided M-mode, blood
pool and tissue Doppler echocardiography. Echocardiogra-
phy was performed by experienced cardiac technicians
using either a General Electric VIVID 7 system or a Philips
7500 Sonos System, with a 2.5 mHz probe. Measurements
of diastolic function were done in accordance with the most
recent recommendations [14]. Measurements included left
ventricular and atrial dimensions, the peak early (E) and
late (A) diastolic filling velocities, isovolumetric relaxation
time (IVRT), deceleration time (slope) of the early peak
filling (DCT). Furthermore, using tissue Doppler imaging,
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septal, anterior, and inferior wall areas, and subsequently
averaged (mean E′). E/E′ was calculated by dividing the
peak early diastolic filling (E) by the average E′ measured
using tissue Doppler imaging. In one centre (University
Medical Centre Groningen), colour coded tissue Doppler
(ccTDI) instead of pulsed wave tissue Doppler (pwTDI)
was used. A recent comparison between ccTDI and pwTDI
was conducted and yielded the following conversion
formulas: E0 pwTDI ðÞ ¼ 1:6 þ 1:2   E0 ccTDI ðÞ ] and E=E0
pwTDI ðÞ ¼ 1:3 þ 0:6   E=E0 ccTDI ðÞ : We therefore pre-
sented all data as pwTDI. Relative wall thickness (RWT)
was calculated as (interventricular wall thickness + left
ventricular posterior wall thickness)/left ventricular end-
diastolic diameter.
Neurohormonal markers
Venous blood samples and urine samples were taken at the
outpatient clinic while the patient was in an upright
position. The blood and urine samples were transported to
the local laboratory immediately and each aliquot was
processed and stored according to protocol for later batched
analysis. The concentration of aldosterone was measured by
a sandwich radioimmunoassay (Diagnostic Products Cor-
poration, Breda, the Netherlands). Active renin protein was
measured by an immunoradiometric assay (Nichols Insti-
tute Diagnostics, Middlesex, United Kingdom) and serum
ACE activity was measured by an enzymatic assay
(Bühlmann Laboratory AG, Schünenbuch, Swiss). NT-
probrain natriuretic peptide (NTproBNP) was measured by
an Elecsys NT-proBNP immunoassay (Roche Diagnostics,
Mannheim, Germany). Renal function was expressed as
estimated GFR (eGFR), calculated with the simplified
MDRD formula [15]. Analyses were performed in a routine
setting according to the guidelines of the manufacturer.
Statistical analysis
The EEND study is considered to be a pilot study. As no
data were available on this subject at the time of initiation
of the study, formal calculation of the sample size was not
performed. Participants who met all inclusion criteria and
had no exclusion criteria were randomized in a 1:1 ratio to
standard treatment or standard treatment combined with
eprosartan 600 mg once daily. Between-group differences
were analyzed according to the intention-to-treat principle.
Endpoints of interest were:
a) Change in diastolic function, measured with the mean
tissue Early (E′) velocity;
b) Change in diastolic function, measured with E/E′;
c) Change in neurohormonal markers
Data were analyzed using SAS version 9.1. Continuous
variables were expressed as means±SD or as median [25–
75% interquartile range], where applicable. Nominal vari-
ables are expressed as n (%). Baseline characteristics were
analysed for difference over treatment group by using
student’s t test or Mann-Whitney U test where applicable
for continuous variables and by chi-square using nominal
variables. The effects of eprosartan on diastolic function
were evaluated using student’s t test or Mann-Whitney U
test where applicable. The relation between change in blood
pressure (tertiles) and change in NT-proBNP was tested
using ANOVA. A p-value P≤0.05 (two-sided) was consid-
ered statistically significant.
Results
Data were analysed from 97 patients (35 male) aged 65±
10 years who were randomly assigned to 6 months open-
label treatment with either eprosartan (in combination with
Eprosartan Control p-value
N=47 N=50
Mean age (years±SD) 65.2 (±9.7) 63.9 (±9.7) 0.52
% Female 30 (65%) 31 (62%) 0.74
Body mass index 28.7 (±4.2) 29.2 (±5.3) 0.63
Heart failure 11 (23%) 9 (18%) 0.51
Current smoking 8 (17%) 8 (16%) 0.89
Diabetes 5 (11%) 6 (12.0%) 0.51
History of AMI 0 (0%) 2 (4%) 0.17
NT-proBNP (pg/ml) 113 (±101) 125 (±139) 0.63
Creatinin (μmol/L) 84 (±20.8) 80 (±20.6) 0.52
eGFR (sMDRD) ml/min/1.73 m
2 73.5 (±16.0) 78.6 (±16.6) 0.13
Cholesterol (mmol/l) 5.2 (±1.2) 5.2 (±1.0) 0.14
Table 1 Baseline characteristics
AMI acute myocardial infarc-
tion; eGFR estimated glomerular
filtration rate; sMDRD simpli-
fied modification of diet in renal
disease equation
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alone (n=50). Baseline characteristics are depicted in
Table 1. According to the definition of the 2007 Guidelines
of the European Society of Hypertension [16], at random-
ization 2 (2%) patients had normal blood pressure, 2 (2%)
had high-normal blood pressure, 30 (31%) patients had
grade 1, 21 (22%) grade 2, and 10 (10%) grade 3
hypertension, and 32 (33%) were classified as having
isolated systolic hypertension. Twenty patients (21%) had
chronic heart failure. These chronic heart failure patients
were stable and on medication for at least 3 months. Only
few patients had diabetes mellitus (11%).
Anti-hypertensive treatment at baseline and at the end of
follow-up in both groups is depicted in Table 2.A s
expected, more anti-hypertensives were used in the control
group compared with the eprosartan group.
Blood pressure changes
Baseline systolic and diastolic blood pressure were 158±
17 mmHg and 91±10 mmHg, and was comparable between
the eprosartan (157±16 mmHg) and control group (158±
17 mmHg) (Fig. 1). After 6 months of treatment, systolic
blood pressures were significantly lower, both in the
eprosartan group (145±18 mmHg; p<0.001 vs. baseline)
and in the control group (141±18 mmHg; p<0.001 vs.
baseline; p = ns between groups). Changes in systolic (−13±
19 mmHg vs. −16±17 mmHg; p between groups=0.38) and
diastolic blood pressure (−7±10 mmHg vs. −7±10 mmHg;
p between groups=0.74), were similar in the eprosartan and
control groups respectively. The changes in systolic and
diastolic blood pressure between baseline and 6 months are
depicted in Fig. 1.
Echocardiographic changes
The echocardiographic findings at baseline and after
6 months are described in Table 3. Despite a significant
drop in blood pressure, diastolic function remained largely
unchanged in both groups. Mean TDI in the eprosartan
group was 8.0±2.3 cm/s at baseline and 8.3±2.2 cm/s after
6 months, and 8.4±2.1 cm/s and 8.5±2.0 cm/s respectively
at baseline and after 6 months in the control group (Fig. 2).
Mean E/E′ remained unchanged both in the eprosartan
group (baseline: 9.3±4.0; 6 months: 9.4±4.2) and in the
control group (baseline: 8.7±2.5; 6 months: 8.9±3.5); (p =
NS both for changes within and between groups).
Additional analyses showed no correlation between the
changes in SBP and the changes mean TDI (r=−0.06; p=
0.58) or the change in E/E′ (r=0.13; p=0.24).
Changes in neurohormonal markers
In the overall group, no significant effects were found on
neurohormones in both groups between baseline and
6 months of treatment (NT-proBNP: −2.8 pg/ml; p=0.81,
renin +6.1 pg/ml; p=0.06; aldosterone −23 pg/ml; p=0.20;
ACE −0.56 pg/ml; p=0.63) However, aldosterone was
significantly lower after 6 months in the eprosartan group
compared to the control group. (Table 4) Changes in NT-
proBNP and other neurohormonal markers in the eprosartan
and control groups are described in Table 4.
We found no correlation between the change in diastolic
function and the change in NT-proBNP. However, a modest
correlation was found between the reduction in systolic blood
Table 2 Anti-hypertensive drugs other than eprosartan at baseline and at the end of the study at 6 months in the eprosartan and control groups
baseline 6months
Eprosartan (n=47) Control (n=50) p-value Eprosartan (n=45) Control (n=47) p-value
ACE-inhibitor 19 (40%) 24 (48%) 0.45 12 (27%) 24 (51%) 0.02
Betablocker 17 (36%) 18 (36%) 0.97 17 (39%) 24 (51%) 0.23
Calcium-antagonist 9 (19%) 9 (18%) 0.92 11 (24%) 18 (38%) 0.15
Diuretic 12 (26%) 18 (36%) 0.26 20 (44%) 31 (66%) 0.04
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Fig. 1 Changes in systolic blood pressure (SBP) between baseline
and after 6 months in the eprosartan and control group
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Figure 3 shows that the decrease of NT-proBNP was largest
in the highest tertile of drop of SBP between baseline and
6m o n t h s .
Adverse events
There were no serious adverse events reported. A total of
14 adverse events were reported in nine patients, without
differences between groups.
Discussion
The present study shows that treatment with eprosartan and
control treatment in hypertension patients with signs of
diastolic dysfunction resulted in a rapid and sustained drop
in both systolic and diastolic blood pressure. Despite this,
diastolic function remained largely unchanged, both in the
eprosartan group and in the control group, without any
difference between the groups. Overall, no significant
effects on neurohormones were found in both groups,
although the reduction in systolic blood pressure was
associated with the reduction in NT-proBNP.
No improvement of diastolic function after lowering blood
pressure
Data on the effects of the treatment of blood pressure on
diastolic function, measured with tissue Doppler, are scarce.
A few studies demonstrated an improvement of diastolic
function after blood pressure lowering therapies [7–11]. In
contrast, one study did not demonstrate beneficial effects of
losartan on diastolic function in patients with hypertension
[12]. However, these studies either did not have a controlled
design, or suboptimal echocardiographic measurements
for diastolic function were used. Two randomised controlled
studies demonstrated beneficial effect of blood lowering
therapies on diastolic function in patients with hypertension
[6, 13]. In the Swedish Irbesartan Left Ventricular Hyper-
trophy Investigation vs Atenolol (SILVHIA) study, both
Table 3 Echocardiographic characteristics
Eprosartan Control p-value between groups at 6months
Baseline 6months Baseline 6months
E/A ratio 0.85 (±0.26) 0.85 (±0.17) 0.84 (±0.21) 0.93 (±0.26) 0.09
DC time (ms) 238 (±48) 240 (±58) 246 (±60) 221 (±50) 0.83
IVRT (ms) 102 (±24) 99 (±21) 103 (±27) 103 (±24) 0.39
Mean E′(cm/s) 8.0 (±2.3) 8.3 (±2.2) 8.4 (±2.1) 8.5 (±2.0) 0.48
LVMI (g/m2) 110 (±37) 102 (±36) 106 (±27) 110 (±27) 0.31
RWT (mm) 0.44 (±0.10) 0.43 (±0.12) 0.46 (±0.12) 0.45 (±0.14) 0.47
E/E′ 9.3 (±4.0) 9.4 (±4.2) 8.7 (±2.5) 8.9 (±3.5) 0.50
LA diameter 38 (±4.5) 38 (±4.7) 38 (±5.1) 38 (±5.3) 0.54
LVEF (%) 58.0 (±4.2) 58.0 (±3.5) 58.4 (±3.1) 57.6 (±5.4) 0.69
Septal wall (mm) 10.5 (±2.9) 10.5 (±2.4) 10.6 (±1.8) 10.7 (±2.0) 0.62
Posterior wall (mm) 10.1 (±1.6) 10.5 (±4.2) 10.3 (±1.6) 10.2 (±1.5) 0.65
LVEDD (mm) 47.8 (±4.9) 45.4 (±9.3) 46.3 (±5.8) 47.4 (±7.0) 0.26
LVESD (mm) 29.6 (±6.2) 28.3 (±7.5) 30.0 (±4.5) 26.1 (±7.5) 0.17
PVa (cm/sec) 32.4 (±6.3) 33.5 (±13.0) 33.2 (±10.3) 32.0 (±12.9) 0.59
DC deceleration; IVRT isovolumetric relaxation time; LVMI left ventricular mass index; LVEF left ventricular ejection fraction; LA left atrium;
LVEDD left ventricular end diastolic diameter; LVESD left ventricular end systolic diameter; PVa pulmonary vein atrial flow reversal. RWT
relative wall thickness
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Fig. 2 Changes in diastolic function (mean tissue Doppler velocity E′
mean and E/E′) between baseline and after 6 months in the eprosartan
and control group
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hypertensive patients [6]. In the VALIDD study, diastolic
function at baseline was comparable with our study [13].
Mean TDI significantly decreased in both treatment arms,
but not E/E′. In contrast to our study, they found that patients
with larger blood pressure reductions had larger improve-
ments of diastolic function. In the Hong Kong diastolic heart
failure study, patients with diastolic heart failure were
randomised to either a diuretic alone, a diuretic plus an
ACE-inhibitor, or a diuretic plus an angiotensin receptor
blocker [17]. In this study, neither the ACE-inhibitor, nor the
angiotensin receptor blocker (irbesartan) affected diastolic
function, quality of life, or 6 min walk test [17]. In addition,
similar to our study and VALIDD, no improvement in E/E′
was seen, while there was only a modest improvement in
mean TDI [17]. Therefore, evidence exists for a beneficial
effect of blood pressure lowering therapy on diastolic
function.
In contrast, our study did not demonstrate an improve-
ment on diastolic function in patients with hypertension,
despite a significant drop in blood pressure. One explanation
might be that tissue Doppler values of the patients in the
present were similar to those reported in an age-matched
general population [18]. However, diastolic function was
comparable with patients in VALIDD, and worse compared
with the SILVHIA study. Both in VALIDD and in SILVHIA,
anti-hypertensive therapy improved diastolic function. A
more likely explanation therefore might be that the treatment
period of 6 months might not have been sufficient to show
an effect on diastolic function. The association between
lowering blood pressure and a decrease in NT-proBNP might
indicate that although cardiac stress has diminished, this is
not yet translated into structural cardiac changes.
No superiority of an angiotensin receptor blocker
over other blood pressure lowering drugs
Our finding that eprosartan was not superior compared with
other anti-hypertensive drugs in improving diastolic function
is consistent with findings in VALIDD and the Hong Kong
diastolic heart failure study [13, 17]. In VALIDD, the effects
of valsartan were not superior to control treatment in
improving diastolic function [13]. In the Hong Kong heart
failure study, the addition of ramipril or irbesartan to a
diuretic was not better in improving diastolic function than a
diuretic alone, although these patients were different from
the present study, since they were all diasto0lic heart failure
patients [17]. So, despite their marked effects on fibrosis and
left ventricular hypertrophy, angiotensin receptor blockers do
not seem to be superior to other anti-hypertensive drugs.
Taken together with the finding that diastolic function did
not improve after lowering of blood pressure in both groups,
one might suggest that neither angiotensin receptor blockers
nor other anti-hypertensive drugs have marked effects on the
improvement of diastolic function. These findings might also
explain why large randomised clinical trials with ACE-
inhibitors, angiotensin receptor blockers, and beta-blockers
in patients with diastolic heart failure showed limited effects
on clinical outcome [19–22].
Changes in neurohormonal markers after anti-hypertensive
treatment
It is well known that ARBs lower aldosterone levels, as was
also found in the present study. These findings were not
Table 4 Laboratory changes in the eprosartan and control groups
Baseline 6months Change
Eprosartan Control Eprosartan Control p-value Eprosartan Control p-value
NT-proBNP 113 (±101) 125 (±139) 134 (±144) 103 (±92) 0.25 +21 (±98) −23 (±110) 0.06
Aldosterone 274 (±158) 294 (±210) 227 (±151) 298 (±169) 0.04 −45 (±130) −5 (±193) 0.26
Renin 15 (±11) 54 (±120) 15 (±8) 14 (±12) 0.26 +7 (±6) +5 (±10) 0.72
ACE 26 (±15) 32 (±20) 30 (±16) 31 (±23) 0.76 +2 (±12) −1 (±9) 0.32
N
T
-
p
r
o
B
N
P
 
C
h
a
n
g
e
 
(
p
g
/
m
l
)
-80
-60
-40
-20
0
20
40
60
< - 22.2 mmHg -22.2 to -8.1 mmHg > -8.1 mmHg
p = 0.04
SBP change
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6 months, divided in tertiles, related to changes in NT-proBNP
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we did not find a significant drop in NT-proBNP, neither in
the eprosartan nor in the control group. However, blood
pressure reduction was related to a decrease in NT-proBNP.
This might suggest that blood pressure lowering does result
in a decrease in cardiac stress, which is not recognized or
followed by a decrease in left ventricular hypertrophy or an
improvement in diastolic function after 6 months of
treatment. However, NT-proBNP might be a sensitive and
early marker that might only translate into functional and
structural changes after more than 6 months of treatment. In
VALIDD, no data on (NT-pro)BNP are reported. In the
Hong Kong diastolic heart failure study however, only the
combination of diuretics and ramipril significantly reduced
NT-proBNP, while diuretics alone or the combination of
diuretics and irbesartan did not. Of note, all patients in the
Hong Kong diastolic heart failure study had heart failure,
while in our study only 20 patients (21%) had heart failure.
In the present study, a total of 20 patients were reported by
their treating physician as having diastolic heart failure.
However, patient characteristics, including systolic and
diastolic left ventricular function and NT-proBNP were
not significantly different between the groups. Therefore,
although the diagnosis of heart failure in these patients is
highly debatable, they did not differ from patients without
heart failure, and did not influence the results.
Limitations
Several limitations of the present study should be noted. First,
the most obvious reason for a lack of effect on diastolic
function might be related to the duration of treatment of
6 months. It seems reasonable to believe that structural and
functional cardiac changes only occur after a longer duration
of treatment. The duration of 6 months was chosen, since an
effect was anticipated already within 6 months. Second,
diastolic function inthese patients was not verypoor. Mean E′
was 8.2 cm/s and mean E/E′ was 9.0, indicating that diastolic
function was only mildly impaired. However, data were
comparablewiththeVALIDDstudy[13]. Third,patientswere
included on the basis of the traditional mitral valve inflow
Doppler parameters. Patients were included when they had an
invertedE/Aratio,andeitheranincreaseddecelerationtimeor
an increased isovolumetric relaxation time. At the time of
initiation of the study, these measurements were usual clinical
practice, although first reports on the superiority of tissue
Doppler for the measurement of diastolic function were just
presented. Fourth, the group was small, and this may have
limited the power to detect smaller differences. Fifth, ACE-
inhibitors were allowed in both groups, which may have
obscured the difference between RAS-blocked versus non-
RAS blockade. In fact, in the eprosartan group, the use of
ACE-inhibitors dropped from 40% to 27% after 6 months,
while in the control group the use of ACE-inhibitors had
slightly increased from 48% to 51%.
Future perspectives
The present and other studies have indicated that the effects
of lowering blood pressure, either with an angiotensin
receptor blocker or with any other anti-hypertensive drug,
do not seem to markedly improve diastolic function. In
addition, large randomized clinical trials showed limited
effects of ACE-inhibitors, angiotensin receptor blockers, or
beta-blockers, on clinical outcome in patients with diastolic
heart failure [19–22]. It therefore remains to be established
how to treat diastolic heart failure [24, 25]. An interesting
novel approach might be to prevent cardiac and vascular
collagen crosslink formation with advanced glycation end
product (AGE)-breakers [26, 27]. First data have indicated
that these agents can improve diastolic function, and further
phase II studies currently ongoing [28].
Conclusion
In patients with hypertension and mildly impaired diastolic
function, neither eprosartan nor other anti-hypertensives did
show any improvement in diastolic function or NT-proBNP
after 6 months of treatment. However, lowering blood
pressure was related to a decrease of NT-proBNP.
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